SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

ProMIS Neurosciences Inc. (ARFXF)

ARFXF RSS Feed
Add ARFXF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/31/2017 12:43:51 PM - Followers: 1 - Board type: Free - Posts Today: 0

ProMIS Neurosciences Inc. 1920 Yonge Street Suite 200 Toronto, ON M4S 3E2 Canada 416-847-6898 http://www.amorfix.com ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops therapeutics and diagnostics for the treatment of neurodegenerative diseases in Canada. It develops technology for treatment of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease (AD). The company has strategic alliances with Epitomics Inc. to develop murine monoclonal antibodies; and license agreement with Biogen Idec for developing therapeutics to treat ALS. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences Inc. in July 2015. ProMIS Neurosciences Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ARFXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
ARFXF News: Amorfix announces fiscal 2014 year end results 06/13/2014 06:00:00 PM
ARFXF News: William Wyman appointed Amorfix Chairman of the Board 06/12/2014 07:30:00 AM
PostSubject
#23   ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for xr_biotech_consult 05/31/17 12:43:51 PM
#22   rdy 4 new high xr_biotech_consult 05/27/17 04:27:09 PM
#21   Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May xr_biotech_consult 05/27/17 04:25:56 PM
#20   DIRECTOR ANTHONY GIOVINAZZO ACQUIRES 150,000 SHARES OF STOCK xr_biotech_consult 05/24/17 04:43:42 PM
#19   ProMIS Neurosciences Designates PMN350 its Second Lead Product xr_biotech_consult 05/24/17 04:41:48 PM
#18   NEW HIGH xr_biotech_consult 05/05/17 04:03:03 PM
#17   Our lead program PMN310 is on track to xr_biotech_consult 05/04/17 01:02:17 PM
#16   We've met all our milestones. xr_biotech_consult 05/04/17 12:59:12 PM
#15   This will bankrupt health care systems if we xr_biotech_consult 05/04/17 12:57:14 PM
#14   "Our objective is to develop best-in-class therapy for Alzheimer's." xr_biotech_consult 05/04/17 12:42:19 PM
#13   the ProMIS of an Alzheimer's Cure xr_biotech_consult 05/04/17 12:40:39 PM
#12   Director Anthony Giovinazzo bought 138,500 shares of Promis xr_biotech_consult 04/28/17 08:23:51 AM
#11   TORONTO, April 27, 2017 /CNW/ - ProMIS Neurosciences xr_biotech_consult 04/27/17 10:30:49 AM
#10   what a day, total breakout ahead xr_biotech_consult 04/27/17 10:30:23 AM
#9   weee :-) xr_biotech_consult 04/25/17 03:27:29 PM
#8   great day, breakout ahead? xr_biotech_consult 04/17/17 04:06:00 PM
#7   ProMIS Neurosciences announces overview of first quarter 2017 xr_biotech_consult 03/30/17 01:27:19 PM
#6   ProMIS Neurosciences : announces five novel Alzheimer's disease xr_biotech_consult 01/07/17 04:14:27 AM
#5   ProMIS Neurosciences : Declares PMN 310 its First xr_biotech_consult 01/07/17 04:13:41 AM
#4   ProMIS Neurosciences : Is This A Cure for xr_biotech_consult 01/07/17 04:12:37 AM
#3   ProMIS Neurosciences initiates groundbreaking Cohort Study xr_biotech_consult 01/07/17 04:10:49 AM
#2   ARFXF bullish 0.1041 stocktrademan 10/07/16 04:44:32 PM
#1   ARFXF bullish 0.116 stocktrademan 08/19/16 09:46:15 AM
PostSubject